Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Cash from Financing Activities (2021 - 2025)

Historic Cash from Financing Activities for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to -$137178.0.

  • InMed Pharmaceuticals' Cash from Financing Activities fell 11636.5% to -$137178.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $11.3 million, marking a year-over-year increase of 124727.97%. This contributed to the annual value of $12.3 million for FY2025, which is 16365.79% up from last year.
  • InMed Pharmaceuticals' Cash from Financing Activities amounted to -$137178.0 in Q3 2025, which was down 11636.5% from $8.2 million recorded in Q2 2025.
  • InMed Pharmaceuticals' 5-year Cash from Financing Activities high stood at $10.9 million for Q3 2021, and its period low was -$836144.0 during Q4 2021.
  • Its 5-year average for Cash from Financing Activities is $2.9 million, with a median of $838239.0 in 2024.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 11730.69% in 2023, then surged by 464453125.0% in 2025.
  • InMed Pharmaceuticals' Cash from Financing Activities (Quarter) stood at -$836144.0 in 2021, then surged by 735.69% to $5.3 million in 2022, then plummeted by 101.2% to -$63697.0 in 2023, then soared by 631.46% to $338521.0 in 2024, then crashed by 140.52% to -$137178.0 in 2025.
  • Its Cash from Financing Activities stands at -$137178.0 for Q3 2025, versus $8.2 million for Q2 2025 and $2.9 million for Q1 2025.